The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma.

Publication date: Jan 10, 2020

Telomerase reverse transcriptase (TERT) copy number gain is frequently observed in Asian melanoma patients. Here, we explored the correlation between TERT copy number and the effect of telomerase inhibitors in melanoma. A total of 78 melanoma cases were enrolled in the study. The TERT copy number was examined by QuantiGenePlex DNA assay. The sensitivity to telomerase inhibitors was evaluated in cell lines and patient-derived xenograft (PDX) models with or without TERT copy number gain. Among the 78 patients, 33.3% showed TERT copy number gain, and the incidence of this gain in acral melanoma (61.5%) was higher than that in other melanoma subtypes (p=0.02). The telomerase inhibitors 6-Thio-dG and EGCG inhibited cell viability and repressed tumor growth in PDX models with TERT copy number gain.TERT copy number gain is frequently observed in Chinese patients with melanoma. Targeting telomerase may benefit melanoma patients with TERT copy number gain.

Yu, J., Yu, J., Wu, X., Guo, Q., Yin, T., Cheng, Z., Dai, J., Kong, Y., and Guo, J. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma. 25436. 2020 Clin Sci (Lond).

Concepts Keywords
Asian Nucleic acids
Assay Telomerase
Chinese Senescence
Correlation Ribonucleoproteins
EGCG DNA replication
Incidence Branches of biology
Melanoma Telomeres
Reverse Transcriptase Melanoma
Sci Asian melanoma
Telomerase Higher melanoma
TERT Tumor
Tumor Acral lentiginous melanoma


Type Source Name
drug DRUGBANK Pralatrexate
pathway KEGG Melanoma
disease MESH melanoma
disease MESH growth
disease MESH tumor
drug DRUGBANK Epigallocatechin gallate

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *